AF
GTHX

Advisornet Financial’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Advisornet Financial’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5
Closed – – 1849
2020
Q4 		$0 Buy
+5
New +$75 ﹤0.01% 1868

Other funds holding GTHX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Advisornet Financial's GTHX Position: Q1 2021 in Review

Advisornet Financial sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2021, closing a stake of 5 shares.

Advisornet Financial first reported a position in GTHX in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 123 funds tracked by Wall St. Rank hold GTHX as of Q1 2021.

  • Advisornet Financial reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Advisornet Financial sold 5 G1 Therapeutics, Inc. Common Stock shares in Q1 2021.
  • Advisornet Financial first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Advisornet Financial's G1 Therapeutics, Inc. Common Stock position peaked at $0 in Q4 2020.
  • 123 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Advisornet Financial's 13F filing for Q1 2021, filed 14 Apr 2021.